Aurora Cannabis Inc(ACB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:37 PM ET (Korea 9/12 05:37)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.41 | Insider Own | 0.62% | Shs Outstand | 64.8M | Perf Week | -3.86% |
| Market Cap | 0.24B | Forward P/E | 49.39 | EPS next Y | 161.79% | Insider Trans | - | Shs Float | 64.4M | Perf Month | -2.09% |
| Enterprise Value | 0.15B | PEG | - | EPS next Q | -0.05 | Inst Own | 9.52% | Short Float | 11.35% | Perf Quarter | 21.43% |
| Income | -0.08B | P/S | 1.16 | EPS this Y | 86.25% | Inst Trans | -0.06% | Short Ratio | 5.04 | Perf Half Y | 6.55% |
| Sales | 0.21B | P/B | 0.64 | EPS next 5Y | - | ROA | -5.24% | Short Interest | 7.31M | Perf YTD | -11.37% |
| Book/sh | 5.87 | P/C | 2.31 | EPS past 3/5Y | 36.88% 45.34% | ROE | -7.1% | 52W High | -43.89% ($6.66) | Perf Year | -24.14% |
| Cash/sh | 1.62 | P/FCF | - | Sales past 3/5Y | 9.84% 3.95% | ROIC | -20.99% | 52W Low | 46.09% ($2.56) | Perf 3Y | -58.94% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -486.67% | Gross Margin | 9.77% | Volatility(W/M) | 3.89% 4.2% | Perf 5Y | -94.36% |
| Dividend TTM | - | EV/Sales | 0.73 | Sales Y/Y TTM | -18.23% | Oper. Margin | -56.85% | ATR (14) | 0.15 | Perf 10Y | -96% |
| Dividend Ex-Date | - | Quick Ratio | 2.8 | EPS Q/Q | 75.83% | Profit Margin | -38.37% | RSI (14) | 52.68 | Recom | 2.43 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.36 | Sales Q/Q | -31.07% | SMA20 | -3.82% ($3.89) | Beta | 0.65 | Target Price | $3.85 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/5 | SMA50 | 14.8% ($3.26) | Rel Volume | 0.56 | Prev Close | $3.73 |
| Employees | 1028 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 61.54% 0.36% | SMA200 | 3.1% ($3.63) | Avg Volume(3M) | 1.45M | Price | $3.74 |
| IPO | 2014/7/11 | Option/Short | Yes/Yes | Trades | 2522 | Volume | 810,645 | Change | 0.27% |
Company
ACB is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🌿 Headquartered in Alberta, Canada, this is a global medical and recreational cannabis cultivation and distribution company. Established in 2013, it operates a vertically integrated business structure spanning from cultivation to derivative product development and distribution, and runs operations across multiple countries in the global medical cannabis market.
Over the past 1 year, roughly in the middle
44% below its 1-year high.
ACB has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +86.3% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -58.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 9.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
YOLO 0.01%
GWX 0.00%
DFIC 0.00%
DFIS 0.00%
RACK 0.00%It ranks #4 in the industry
Based on market cap of $243M.
ACB $243M PER -
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is ACB?
ACB belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ACB?
The market cap of ACB is approximately $243M, ranking 3,948 within its sector.
What is the 52-week high and low for ACB?
ACB has recorded a 52-week high of $6.66 and a low of $2.56.
